A REVIEW UPDATED ON CHEMOTHERAPEUTICS by Chandra, Akanksha et al.
Chandra et al                                           Journal of Drug Delivery & Therapeutics; 2013, 3(6), 192-197    192 
© 2011, JDDT. All Rights Reserved                                                          ISSN: 2250-1177                                                   CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
REVIEW ARTICLE 
A REVIEW UPDATED ON CHEMOTHERAPEUTICS 
*Akanksha Chandra
1
, Rajesh Kr. Soni
2
, Upendra Sharma
1
, Sanjay Kr. Jain
2
, Prayag Yadav
2
 
1
Institute of Pharmacy, Department of Pharmaceutics, Bundelkhand University, Jhansi (U.P), India 
2
Institute of Pharmacy, Department of Pharmacognosy, Bundelkhand University, Jhansi (U.P), India 
*Corresponding author’s Email Id: acshrishti@gmail.com 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION: 
Chemotherapy continues to play a crucial role in the 
modern management of cancer. Another name for 
chemotherapy is cytotoxic therapy. The cancer cells grow 
at a faster rate as compared to the normal cells. The basis 
on which most of the chemotherapeutic drugs work is that 
they target the fast growing cells in the body minimally 
disturbing the cells growing slowly. The basic aim of 
chemotherapy is to kill the cancerous cells with minimal 
damage to the other healthy cells in the body. The 
chemotherapeutic drugs have been categorized into 
different categories. The small-molecule drugs are the ones 
whose molecular weight is less than 1000 Daltons.The 
action of antineoplastic drugs is not selective for neoplastic 
cells, sothat they have quite considerable side effects that 
are mainly evident in cell lines expressing higher growth 
and replication rates. Furthermore, antineoplastic drugs 
may evidence a degree of selective toxicity on particular 
organs, mainly the lungs, the liver, the kidneys and the 
nervous system structures. They may (and do) also induce 
derangements in the replication and processing 
mechanismsof the cells involved in immune responses, so 
that their use leads to a state of immune depression 
facilitating the development of bacterial, viral and fungal 
infections. In the long run they also cause other forms of 
toxicity, such as mutagenicity and carcinogenesis. 
Cancer and Chemotherapy: 
Cancer is the condition where the cells in the body 
increase and divide beyond limit. These cells slowly start 
spreading to the nearby tissues and then into the blood 
stream. In the developed nations cancer holds second 
position for causing the death of the people. The increase 
in pollution has lead to an increase in the cases of lung 
cancer while the longevity of life has increased the cases 
of colon cancer; the picture today shows that oneout of 
every 8 women suffers from breast cancer. The treatment 
procedure of cancer includes radiations, medication and 
above all the use of chemotherapy for the destruction of 
the cancer cells
1
. 
Almost 75 years ago, the researchers explored the fact that 
cancer affects the mitochondria. We are aware that 
mitochondria obtain energy for oxidizing the sugar 
glucose. In a tumor cells the mitochondria stops 
functioning and the glucose is broken down in the absence 
of oxygen. We are aware that mitochondria obtain energy 
for oxidizing the sugar glucose. In a tumor cells the 
mitochondria stops functioning and the glucose is broken 
down in the absence of oxygen. This suppression of the 
mitochondria in the cancer cells alters the metabolism 
process and helps the cancer cells to grow, acting as 
resistance against much standard chemotherapy
2
. 
Recommendations for the prevention of 
hypersensitivity reactions to chemotherapeutic drugs: 
Prevention of hypersensitivity reactions caused by 
antineoplastic drugs (from Weiss, modified)
3
. 
Premedication: 
 Dexamethasone 20 mg p.o. 12 and 6 h before therapy, and 
20 mg i.v. immediately before therapy 
 Dexchlorphenyramine 6 mg p.o. or 5 mg i.v., with the 
same schedule as for dexamethasone  
 Consider ephedrine sulfate 25 mg p.o. 1 hour before 
therapy unless the patient has unstable angina pectoris or is 
hypertensive  
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 Careful suppression (whenever possible) of any ß-
blocking medicationthat might potentiate a reaction or 
hamper its management 
Particular measures during therapy administration 
 Maintain a venous access 
 Arterial blood pressure monitoring (if available) 
 Ensure that epinephrine and diphenhydramine for 
parenteraladministration are immediately available 
 Keep the patient under observation for two hours after 
theadministration of the antineoplastic drug is finished 
Different Categories of Chemotherapeutic Drugs: 
Most of the chemotherapeutic agents destroy the cancer 
cells by targeting the DNA functions. The different 
categories of chemotherapy agents are all follows
4
: 
1. Alkylating agents 
2. Antimetabolites 
3. Plant alkaloids 
4. Anthracyclines 
5. Antitumor antibiotics 
6. Platinums 
7. Taxanes 
Alkylating Agents:  
These are the oldest class of anticancer drugs which attack 
the negatively charged sites on the DNA (oxygen, 
nitrogen, sulfur atoms and phosphorous). 
Antimetabolites:  
The antimetabolites intervene with usual metabolic 
pathways and involve the use of folic acid for preparing 
fresh DNA. Antimetabolites inhibit DNA synthesis and 
helps in DNA repair. Methotraxate, 5-Fluorouracil (5-FU), 
Thioguanine, Cladribine and Fludarabine are some of the 
examples of antimetabolites used for treating leukemia, 
breast, head, neck, colon, pancreatic, esophageal, anal and 
bladder cancer, lymphoma and sarcoma. 
Plant Alkaloids:  
Plant alkaloids are obtained from plant materials and are 
redivided into four groups namely taxanes, vinca 
(vincristine, vinorelbine and vinblastine), and 
topoisomerase inhibitors (irinotecan and topotecan) 
andepipodophyllotoxins (Etoposideand Teniposide) 
alkaloids. 
Anthracyclines:  
These drugs are prepared from natural sources help in the 
formation of the free oxygen radicals which result in DNA 
constituents break up following inhibition of DNA 
synthesis. According to Johns Hopkins Medical 
Institutions
5
, for around four decades anthracycline class 
of chemotherapeutics such as epirubicin, idarubicin, 
doxorubicin (Adriamycin) and daunorubicin have been 
used for the treatment of different types of cancer like 
sarcomas, carcinomas, leukemia and 
lymphoma.Researches are still on its way to strengthen the 
fact that it would be helpful to use DCA to sensitize the 
tumor cells to apoptosis and then expose the patient to 
chemotherapeutic drugs. Because in that case even the 
lower dose of chemotherapeutic drugs would prove 
effective as the tumor cells become weak and lose 
immunity
2.
The major drawback of these drugs is cardiac 
toxicity. 
Antitumor Antibiotics: 
Antitumor antibiotics work on the same line as that of 
anthracyclines.Example of antitumor antibiotics includes 
Bleomycin used for treating Hodgkin’s lymphoma and 
testicular cancer. 
Platinums:  
Platinums include the use of natural metal derivatives in 
order to fightagainst cancer. These agents help in cross-
linking the DNA subunits that helps in DNAsynthesis, 
transcription and function. Examples of platinums include 
cisplatin (first-generation platinum), carboplatin (second 
generation platinum) and oxaliplatin (third generation 
platinum). 
Taxanes:  
The taxanes are new class of anticancer agents exerting 
their cytotoxic effectson the cancer cells though an 
exceptional procedure. 
Taxol or Paclitaxel 
Taxol or Paclitaxel, first taxane in clinical trials, is used in 
the treatment of testis, lungs,head, neck, lung and 
metastatic breast cancer. It is generally considered 
refractory toconventional chemotherapy and hence has 
been approved in the U. S. and other nations intreating 
patients with ovarian and breast cancer, which resist 
chemotherapy. This hasbeen approved as the palliative 
therapy.The tree is a scarce and slow-growingevergreen 
tree found in the forests of the Pacific Northwest and is 
also found to havecytotoxic effect against different 
tumors
6
. 
 
Structure of Taxol
7 
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Mode of Action of Taxol 
Polymers of tubulin are present in microtubules with alpha 
and beta protein subunits present in the tubulin 
heterodimers. The microtubules performs some crucial 
functions like formation of the mitotic spindle during the 
cell division and other interphase functions like 
maintaining the shape, signal transmission, motility and 
intracellular transportation
8,9,10,11
side effects may include: 
1. Optic-nerve disturbance and scotomata. 
2. Transient myalgia 
3. Myopathy 
4. Transient asymptomatic bradycardia
12
 
5. Bradyarrhythmias like Mobitz type I and type II. 
6. Third degree heart block 
7. Fluid retention 
8. Allergy 
9. Hair loss 
10. Anemia 
11. Low platelet and white blood count 
12. Allergic reaction 
13. Nerve destruction 
14. Diarrhea 
15. Soreness of mouth with difficulty in swallowing 
16. Skin infection 
17. Myocardial infarction 
18. Cardiac ischemia 
19. Atrial arrhythmias 
Vaccines Along with Chemotherapy 
Cancer vaccines to control cancer growth and stop people 
from becoming victim of the disease are also being 
developed. Although, the research is only at its initial stage 
but is sure to give some fruitful results soon. These 
vaccines are being prepared by using not just a particular 
cell protein that is antigen but the entire cancer cell for 
preparing the vaccine. The cancer cell may be from the 
patient’s own body, or it may be another person’s cell. It 
can also be the one grown in the laboratory. Some vaccines 
are notsuitable to be given along with the chemotherapy
13
. 
Limitations of Chemotherapy 
The adverse effects of chemotherapy include neurological 
problems, stress, emotional imbalances, depression, 
physical and emotional disorders of the heart. In women 
chemotherapy may lead to bleeding, bruising, infections 
and anemia. When chemotherapy is given to the patient it 
leads to the destruction of all types of cells along with the 
cancer cells, which are red blood cells, white blood cells 
and platelets. Hence, there is a heavy loss of all types of 
cells from the body and the body is more likely to become 
a victim of infections and experiences weakness during 
and post chemotherapy. It is therefore preferable to have 
the laboratory data of the patient before beginning with 
chemotherapy.The patient may experience dryness of 
mouth, sticky saliva and dark yellow urine with reduced 
urine output. These signs indicate dehydration in the body 
and medicines are usually recommended by the doctor to 
control them. Dryness in the vaginal area may also be seen 
in women with a decreased crave towards sex and 
alteration in their emotional and physical fitness. 
Oral Manifestations of Chemotherapy: 
Chemotherapeutic drugs are administered systemically 
over several weeks or months in a sequence of "treatment 
rounds or courses." This schedule allows some recovery of 
healthy tissues between each treatment of the toxic drugs. 
Mucositis and ulceration 
The gastrointestinal (GI) mucosa, because of its high 
cellular turnover rate, is highly susceptible to the toxic 
effects of many chemotherapeutic agents. Inflammation 
and ulceration of the mucosal lining of the mouth, 
pharynx, esophagus and the entire GI tract may occur. The 
patient may experience pain, nausea, vomiting and 
diarrhea. 
Pain 
Oropharyngeal pain is a prominent and frequent sequel of 
chemotherapy- induced mucositis. Descriptions of pain by 
patients do not always correlate with severity of tissue 
injury as assessed upon clinical examination. 
Infection 
Many drugs and some malignancies can suppress bone 
marrow production and induce leukopenia, which can 
result in increased risk of infections. The usual clinical 
signs of inflammation (redness, pain, swelling, heat) may 
not be present during periods of significant 
immunosuppression. If pain is present, the symptomatic 
areas of possible infection (operculum, periodontal pockets 
or mucosal ulcerations) should be cultured if the patient 
develops a fever of unknown origin. Infection may be 
caused by organisms usually found in the mouth such as 
Candida species, herpes viruses, streptococci and 
staphylococci. 
Oral Manifestations of Chemotherapy Bleeding 
Reduction of platelets (thrombocytopenia) and other 
clotting factors during periods of bone marrow suppression 
are the major causes of bleeding. Transfusion of platelets 
and/or clotting factors in conjunction with topical agents 
may be necessary for control. 
Xerostomia/Salivary gland dysfunction 
Patients may complain of decreased or thickened saliva. 
The duration of xerostomia is associated with the length of 
therapy, other prescribed medications and the health of the 
patient. Xerostomia may result in a lowered pH, alterations 
in the constituents of the saliva, and it may lead to rampant 
dental caries. A dry mucosa is more susceptible to pain, 
infections and irritation. 
Taste alteration 
Transient alteration in taste is common after the 
administration of some chemotherapeutic drugs. 
Neurotoxicity 
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The patient may present with numbness or constant, deep 
pain that is often bilateral and frequently mimics toothache 
(odontalgia), but noodontogenic or mucosal source can be 
found. This phenomenon may be present after the 
administration of drugs such as vincristine and vinblastine. 
Dental developmental abnormalities 
Chemotherapy administered during dental development in 
childhood may cause shortened or malformed roots, 
enamel defects, disturbance in crown development and 
eruption. 
Radiation therapy: 
 
 
Potential Oral Manifestations of Radiation Therapy to the Oropharyngeal and Salivary Gland Region 
Acute Chronic 
Taste alterations Salivary gland dysfunction 
Salivary gland dysfunction Radiation caries/demineralization 
Mucositis/Ulceration/Pain Trismus/TMD 
Infection Soft tissue necrosis - 
Nutritional deficiency/Dysphagia Osteoradionecrosis - 
Developmental maxillofacial deformity - 
 
Factors that influence intensity and duration of the oral 
manifestations 
 total dosage 
 rate of radiation delivery 
 fraction size 
 field of radiation 
 radiation source 
 previous surgical intervention 
 oral hygiene and dental status 
 medical and nutritional status of patient 
 tobacco and alcohol use 
Limitations of Chemotherapy: 
The adverse effects of chemotherapy include neurological 
problems, stress, emotional imbalances, depression, 
physical and emotional disorders of the heart. In 
womenchemotherapy may lead to bleeding, bruising, 
infections and anemia.When chemotherapy is given to the 
patient it leads to the destruction of all types of cellsalong 
with the cancer cells, which are red blood cells, white 
blood cells and platelets.Hence, there is a heavy loss of all 
types of cells from the body and the body is morelikely to 
become a victim of infections and experiences weakness 
during and postchemotherapy. It is therefore preferable to 
have the laboratory data of the patient beforebeginning 
with chemotherapy. 
In adults, cytotoxic chemotherapy became established in 
the1970s as a curative treatment in advanced Hodgkin’s 
disease
14
, non-Hodgkin’s lymphoma15, teratoma of testis16 
and as an adjuvant treatment for early breast cancer
17
. The 
initial results suggested the potential use of cytotoxic 
chemotherapy as a definitive treatment or as an adjuvant 
therapy in asymptomatic patients with the aim of 
improving survival. However, as stated by Braverman
18 
and others
19,20
 the early gains in a few tumour sites have 
not been seen in the more common cancers. For most 
patients, the use of cytotoxic chemotherapy is for the 
palliation of symptoms and to improve quality of life
21, 
with prolongation of survival being a less important 
outcome. 
Oesophageal Cancer 
The survival for oesophageal cancer is less than 10% at5 
years
22
. For every 100 newly diagnosed patients, onethird 
has metastatic disease (M1) at presentation (n ¼ 33). In the 
remainder (n ¼ 67), only 40% (n ¼ 26) are medically 
operable, and only 80% of these will have a curative 
procedure (n ¼ 21). Those who do not have an operation 
(n ¼ 67 _ 21 ¼ 46) are suitable for treatment by 
radiotherapy or a combination of chemotherapy and 
radiotherapy. 
In a Cochrane review reporting seven RCTs and 1653 
patients
23
, preoperative chemotherapy in resectablethoracic 
cancers was not shown to have a role, but an MRC trial
24
 
and a recent meta-analysis
25 
has confirmed a benefit for 
preoperative chemotherapy. A further Cochrane review
26
of 
combined chemotherapy and radiotherapy compared with 
radiotherapy alone 
for esophageal cancer showed a significant absolute 
improvement in overall survival at 1 and 2 years for 
combined chemotherapy and radiotherapy of 9% and 8% 
respectively, and a 5% absolute reduction in local failure. 
It can be concluded that, when a non-operative approach 
was selected, then concomitant chemotherapy and 
radiotherapy were superior to radiotherapy alone. 
Chemotherapy, therefore,has a curative role in all patients 
except those who areM1 at presentation. This is likely to 
be an overestimate as data were only available for 2-year 
follow-up. 
Stomach Cancer 
Stomach cancer has a 22.6e24.8% 5-year survival
22
, with 
surgery being the only established curative procedure. 
Meta-analyses in 1993
27
 and 1999
28 
suggested that 
adjuvant chemotherapy might produce a small survival 
benefit of borderline significance in curatively resected 
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Colon Cancer 
Surgery is the only established curative treatment forcolon 
cancer, with chemotherapy used as adjuvant treatment. The 
IMPACT Group analysis in 1995 of three separate trials of 
5-fluorouracil and leucovorin in Duke’s B and C colon 
cancer showed an improvement in 3-year 
Disease free survival of 9% and overall survival benefit of 
5%
29
. A further meta-analysis in 1997 compared a no-
treatment control with postoperative chemotherapy 
(excluding liver infusion) in resected colorectal cancer
22
. 
The overall survival benefit for chemotherapy was 5% for 
colon cancer and 9% for rectal cancer. 
Pancreatic Cancer 
Pancreatic cancer has a 5-year survival of just over 5%
22
. 
The impact of gemcitabine is still being evaluated, but a 
recent RCT showed a median survival of 5.4 months, and a 
progression-free survival of 2.2 months with 
gemcitabinealone. An objective response was seen in only 
5.6% of patients, and overall survival at 24 months was 
about 5% 
31
. 
Lung Cancer 
Small-cell lung cancer Incidence: 19% of total (Australia) 
and 13% of total in the USA (SEER). Virtually all patients 
receive initial cytotoxic chemotherapy. The overall 5-year 
survival for small-cell lung cancer (SCLC) is 3.5%, or 
2.5% in limited-stage disease and 1.2% in extensive-stage 
disease
37
. 
Rectal Cancer 
Surgery is the mainstay of treatment, with chemotherapy 
and radiotherapy used as adjuvant treatments. Two RCTs 
show that the combination of radiotherapy and 
chemotherapy decreased local recurrence and increased 
overall survival compared with a no-treatment control
32,33
. 
The NSABP R-02 trial
34 
showed that chemotherapy alone 
improved disease-free survival and overall survival, and 
that radiotherapy alone decreased local recurrence, but had 
no effect on disease-free survival or overall survival. 
 
Anal Cancer 
The combination of radiotherapy and chemotherapy for 
sphincter preservation is now standard management, 
except in advanced disease, in which abdomino-perineal 
resection is still required after radiotherapy and 
chemotherapy. In two RCTs
35,36
, the addition of 
chemotherapy to radiotherapy gave a higher complete 
response rate and colostomy-free survival than 
radiotherapy alone, but there was no effect on overall 
survival. 
Breast Cancer 
The results of adjuvant chemotherapy have been published 
in several overview publications. In 
summary,chemotherapy reduces the rate of recurrence and 
improvessurvival for women with early breast cancer
37,38
. 
No RCTs have reported results of adjuvant chemotherapy 
in women aged 70 years or over, and any benefit in this 
age group is therefore not evidence based. 
CONCLUSION: 
Chemotherapy has an ability to treat widespread cancer as 
compared to radiation therapy and surgery which has a 
limited coverage. There are a number of chemotherapeutic 
agents that are divided into alkylating agents, 
antimetabolites, plant alkaloids, anthracyclines, antitumor 
antibiotics, platinums and taxanes. Other chemotherapeutic 
drugs include includehydroxyurea, thalidomide, 
dactinomycin, and asparaginase. 
Now with the advancement in researches, the drug will be 
able to reach the tumor site within hours instead of normal 
2 days time. Researches are still in progress to make them 
more and more effective with less and less side effects. 
Also, cancer vaccines are being developed to control 
cancer growth although the process is still at an initial 
stage of development. 
The best example of the ‘over-selling’ of chemotherapy is 
in breast cancer, where chemotherapy was introduced as 
the example of the new cure for solid malignancies. 
InAustralia, in 1998, only 4638 of the 10 661 women with 
newly diagnosed breast cancer were eligible for adjuvant 
chemotherapy (44% of total). From our calculations, only 
164 women (3.5%) actually had a survival benefit from 
adjuvant chemotherapy. In other words, on average, 29 
women had to be treated for one additional woman to 
survive more than 5 years. 
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